Beta Synuclein Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Beta-Synuclein Protein |
|---|
| Full Name | Beta-Synuclein |
| Gene | SNCB |
| UniProt ID | Q9NQ88 |
| PDB ID | 1XK8, 1SN3 |
| Molecular Weight | 14 kDa |
| Subcellular Localization | Cytoplasm, presynaptic terminals |
| Protein Family |
| Synuclein family |
Beta-Synuclein is a member of the synuclein family of proteins that includes alpha-synuclein (SNCA) and gamma-synuclein (SNCG). Unlike alpha-synuclein, beta-synuclein is considered neuroprotective and inhibits the aggregation of its more aggregation-prone counterpart.
Beta-synuclein shares the general synuclein structure:
- N-terminal Domain: Amphipathic region with KTKEGV repeats (membrane-binding)
- Central Domain: Non-Aβ component (NAC) region - hydrophobic
- C-terminal Domain: Acidic tail with chaperone activity
The protein is intrinsically disordered and adopts various conformations depending on context.
Beta-synuclein has several important functions:
- Anti-aggregation Activity: Binds to alpha-synuclein and prevents its fibrillization[1]
- Chaperone Function: Has molecular chaperone activity, protecting neurons from stress
- Synaptic Modulation: Localizes to presynaptic terminals
- Dopamine Regulation: Modulates dopamine synthesis and release
In neurons, beta-synuclein appears protective:
- Inhibits alpha-synuclein toxicity
- Protects against oxidative stress
- May have neuroprotective effects in synucleinopathies
- Pathology: SNCB mutations can cause PD with reduced anti-aggregation function[2]
- Mechanism: Loss of protective function enhances alpha-synuclein aggregation
¶ Lewy Body Dementia
- Pathology: Beta-synuclein is a component of Lewy bodies[3]
- Mechanism: May co-aggregate with alpha-synuclein in disease
- Pathology: Beta-synuclein in glial cytoplasmic inclusions[4]
- Mechanism: Oligodendroglial expression contributes to pathology
| Approach |
Description |
Status |
| Beta-Synuclein Gene Therapy |
Overexpress protective beta-synuclein |
Preclinical |
| Aggregation Inhibitors |
Based on beta-synuclein mechanism |
Clinical trials |
| Small Molecule Stabilizers |
Stabilize protective conformation |
Research |
- [1] Hashimoto M et al. (2001). "Beta-synuclein inhibits alpha-synuclein aggregation." Neuron
- [2] Fujioka S et al. (2014). "SNCB mutations in Parkinson's disease." Movement Disorders
- [3] Dickson DW et al. (2010). "Beta-synuclein in Lewy body disease." Acta Neuropathologica
- [4] Wenning GK et al. (2008). "Beta-synuclein in MSA." Brain
Beta-synuclein expression:
- Cerebral cortex: High expression in pyramidal neurons
- Substantia nigra: Moderate in dopaminergic neurons
- Hippocampus: CA regions and dentate gyrus
- Cerebellum: Lower expression
- Cytoplasm: Predominant localization
- Synaptic terminals: Presynaptic enrichment
- Mitochondria: Some mitochondrial association
- Inhibitory function: Prevents alpha-synuclein aggregation
- Hetero-oligomer formation: Forms non-toxic complexes
- Chaperone activity: Protein folding assistance
- Protective role: Potential therapeutic target
- Aggregation blockade: Prevents fibril formation
- Membrane binding: Lipid rafts interaction
- Oxidative stress: Antioxidant properties
- Synaptic protection: Maintains synaptic function
- Recombinant SNCB: Administered exogenously
- Peptide derivatives: Truncated protective regions
- Gene therapy: Viral vector delivery
- SNCB expression enhancers: Increase endogenous levels
- Aggregation inhibitors: Target alpha/beta interaction
- Stabilizing compounds: Maintain protective conformation
- Blood beta-synuclein: Diagnostic biomarker
- CSF levels: Disease progression marker
- ELISA development: Clinical assay validation
- Why does beta-synuclein not form inclusions in disease?
- What determines its protective vs pathogenic effects?
- Can it be harnessed therapeutically?
- What regulates its expression in brain?
The study of Beta Synuclein Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hashimoto M et al. (1997). "Beta-synuclein: A neuroprotective protein." Journal of Neural Transmission. PMID:9182803
- Windisch M et al. (2002). "Beta-synuclein and protein aggregation." Neurochemistry International. PMID:12137749
- Paleologou KE et al. (2008). "Phosphorylation of beta-synuclein." Journal of Biological Chemistry. PMID:18381983